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Abstract
Background Lapatinib is a commonly used drug that
interrupts signaling from the epidermal growth factor
receptors, EGFR and HER2/neu. Long-term exposure to
lapatinib during therapy eliminates cells that are sensitive
to the drug; however, at the same time it increases proba-
bility of lapatinib-resistant cell selection. The aim of this
study was to verify whether combinations of lapatinib with
one of isothiocyanates (sulforaphane, erucin or sul-
foraphene), targeting different levels of HER2 signaling
pathway, exert stronger cytotoxic effect than therapy tar-
geting the receptor only, using heterogeneous populations
consisting of lapatinib-sensitive and lapatinib-resistant
breast cancer cells.
Methods Lapatinib-sensitive HER2 overproducing SKBR-3
breast cancer cells and their lapatinib-resistant derivatives
were combined at different proportions to simulate
enrichment of cancer cell population in a drug-resistant
fraction during lapatinib therapy. Effects of treatments on
cell survival (MTT), apoptosis induction (PARP cleavage),
prosurvival signaling (p-Akt, p-S6) as well as cell motility
(wound healing assay) and invasion (Boyden chamber
assay) were investigated.
Results Combination of lapatinib with any of isothio-
cyanates significantly decreased cell viability and inhibited
migration of populations consisting of different amounts of
drug-sensitive and drug-resistant cells. In case of popula-
tion entirely composed of lapatinib-resistant cells the most
effective was combination of lapatinib with erucin which
decreased cell viability and motility, phosphorylation of
Akt, S6 and VEGF level more efficiently than each agent
alone.
Conclusions Combination of lapatinib and isothio-
cyanates, especially erucin, might be considered as an
effective treatment reducing metastatic potential of breast
cancer cells, even these with the drug resistance phenotype.
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Introduction
Overproduction of HER2 (human epidermal growth factor
receptor 2) is reported in nearly 20–25 % of all breast
cancer cases. Enhanced signal transduction from amplified
receptors, especially through Akt-mTOR-S6K signaling
pathway, leads to uncontrolled proliferation, evasion of
apoptosis, neoangiogenesis and enhanced cell motility,
which may lead to metastasis. It has been reported that
30–40 % of women with breast cancer develop a metastatic
disease [1], and that it may be associated with HER2 gene
amplification [2]. Since overproduction of HER2 correlates
with poor clinical outcomes, this receptor became a target
for anticancer therapies.
Currently, several treatments targeting HER2 are
approved, which include monoclonal antibodies and small
molecule inhibitors of receptor kinases or their combina-
tions with chemotherapeutic agents [3, 4]. Trastuzumab
(Herceptin; Genentech, South San Francisco, CA, USA)
was the first monoclonal antibody developed to target
HER2. It significantly improved outcomes for patients
diagnosed with this subtype of cancer [5]. However, de
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novo or acquired resistance to trastuzumab eventually
occurs in most patients with advanced disease [6]. Thus,
trastuzumab is typically combined with chemotherapy to
increase efficacy, which also increases toxicity. Additional
HER2 targeting agents have been developed recently, such
as pertuzumab or trastuzumab emtansine. Pertuzumab
(Perjeta, Genentech) is a fully humanized monoclonal
antibody that binds to a different epitope of the HER2
extracellular domain than trastuzumab, and prevents
dimerization of the HER receptors [7]. It is effective in
combination with trastuzumab and docetaxel in advanced
breast cancers [8]. In 2013, the FDA approved the first
successful HER2-targeted antibody–drug conjugate, tras-
tuzumab emtansine (T-DM1; Kadcyla; Genentech), for the
treatment of HER2-positive trastuzumab-pretreated
advanced breast cancer. This drug inhibits HER2 signaling
and is cytotoxic to HER2-positive cells due to emtansine
which disrupts dynamics of microtubules [9]. T-DM1
appears to have some activity against central nervous
system metastases [10].
Another class of agents used to block Her-2 signaling
are small molecule tyrosine kinase inhibitors, such as
lapatinib (Tykerb; GlaxoSmithKline, Brentford, United
Kingdom). Mechanism of its action relies on blocking of
the ATP-binding site in the cytoplasmic domain of
HER2 which leads to inhibition of signal transduction
cascade from the receptor [4]. In spite of a great success
in breast cancer therapy, primary or acquired resistance
to lapatinib still occurs, even when this medicament is
used in combination with other commercially available
anti-HER2 agents (e.g., trastuzumab) [11]. Long-term
exposure to lapatinib causes elimination of drug-sensi-
tive cells and at the same time increases probability of
selection of lapatinib-resistant cells whose percentage
increases in the cell population with time. Cancer cells
respond to the first stage of treatment and tumor
decreases, however, appearance of resistant cells, which
typically occurs within 12 months of the start of therapy,
may lead to progression of the disease and to metastasis
[12, 13]. Many different mechanisms underlying this
phenomenon have been proposed, including hyperacti-
vation of the signaling network downstream of HER2
[14].
Overexpression of HER2 is also associated with vas-
cular endothelial growth factor (VEGF) upregulation [15].
It has been shown that most types of human cancer cells
overexpress VEGF and its receptor [16]. VEGF is one of
the most important factors stimulating angiogenesis, which
is essential for the growth of solid tumors. VEGF also
induces expression of matrix metalloproteinases (MMPs)
that degrade the basement membrane, thus it is also
involved in first stages of endothelial cell migration and
metastasis of cancer cells [17].
Recently, we demonstrated that isothiocyantes, such as
sulforaphane (SFN), erucin (ERN) and sulforaphene (SF),
enhance anti proliferative activity of lapatinib in HER2-
positive breast cancer cells which was connected with a
more efficient inhibition of pro survival signaling and
induction of apoptosis [18]. Isothiocyanates (ITC) are
naturally occurring compounds in Brassicaceae vegetables.
They possess chemopreventive activities—inhibit phase I
enzymes, which are responsible for carcinogens activation,
and induce phase II enzymes that are involved in car-
cinogen elimination [19, 20]. Moreover, isothiocyanates
reveal anticancer activity causing apoptosis through
induction of oxidative stress and modulation of numerous
cell signaling cascades which are crucial for cancer cell
survival [21]. It has been previously shown that SFN
inhibits Akt-mTOR survival pathway in leukemia cells
[22] and in breast cancer cells differing in growth factor
receptor status [23]. Importantly, there are reports showing
that SFN more efficiently inhibits growth of human breast
cancer cells than normal breast epithelial cells [24, 25].
Numerous reports indicate that isothiocyanates influence
different signal transduction pathways downstream of
growth factor receptors. For instance, Wu et al. suggested
that phenethyl isothiocyanate (PEITC) and benzyl isoth-
iocyanate (BITC) inhibited cell survival signaling kinase
Akt, and suppressed lung cancer cell metastasis potential
[26]. SFN, one of the best characterized ITC present in
high concentrations in broccoli, decreased phosphorylation
of Akt and S6K1 in MDA-MB-231, MCF-7, MDA-MB-
468 and SKBR-3 breast cancer cell lines [23] and inhibited
Akt and mTOR pathway in acute lymphoblastic leukemia
cells [22]. Moreover, in PC-3 prostate cancer cells, SFN
inhibited activation of NF-jB, Akt and ERK which are all
involved in cancer survival and metastasis [27]. Further-
more, in vivo, SFN inhibited the activation of MMPs and
lung metastasis induced by melanoma cells in mice [28]. It
has been also shown that SFN suppressed capillary-like
tube formation on basement membrane matrix and inhib-
ited HMEC-1 cell migration by down regulation of the
vascular endothelial growth factor (VEGF) and its receptor
KDR/flk-1, hypoxia-inducible factor-1a, c-Myc and matrix
metalloproteinase 2 [29].
In this work we asked a question whether combination
of lapatinib with sulforaphane, sulphoraphene or erucin
overcomes development of the drug-resistant populations
and whether such therapy protects against development of
metastatic breast cancer. We have chosen lapatinib,
because—in contrast to trastuzumab and its derivatives—it
is orally bioavailable drug. Additionally, as a small mole-
cule it is better suited to cross the blood–brain barrier,
which rationalizes its use in patients with metastases to
central nervous system for which HER2-positive tumors
have predilection [30].
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To answer these questions, we designed an in vitro
simulation of the drug-dependent selection of resistant cells
during lapatinib treatment and evaluated anticancer effi-
ciency of combined therapy as compared to lapatinib or
each of ITCs as the only agents. Lapatinib-sensitive and
lapatinib-resistant SKBR-3 cells were combined in differ-
ent proportions to simulate the heterogeneity of cancer cell
populations and were treated with low doses of isothio-
cyanates (close to their IC50), the drug (below its IC50 for
the sensitive cell line) or combinations of compounds.
Their survival and migration potential was evaluated. As
erucin-lapatinib combination was the most effective, we
verified its influence on cell motility, invasion, VEGF level
and HER2 downstream signaling.
Materials and methods
Reagents and cell lines
Lapatinib ditosylate (purity[ 99.5 %), erucin (pu-
rity C 99 %), S-sulforaphene (purity C 99.7 %) and R,S-
sulforaphane (purity C 99 %) were obtained from LKT
Laboratories (St. Paul, MN, USA). DMSO, thiazolyl blue
tetrazolium bromide (MTT), the anti-b-actin, anti-mouse
and anti-rabbit antibodies conjugated with HRP were from
Sigma (St. Louis, MO, USA). The antibodies against p-Akt
(Ser-473), Akt, p-S6 (Ser 235), PARP-1, VEGF from Santa
Cruz Biotechnology (Santa Cruz, CA, USA) and p-HER2
(Tyr121/1222), HER2, S6 were from Cell Signaling
Technology (Danvers, MA, USA).
Lapatinib-resistant SKBR-3 cells (LapR) were devel-
oped by a long-term exposure of SKBR-3 cells to
increasing concentrations of the drug. Cells were cultured
in RPMI 1640 medium supplemented with 10 % fetal
bovine serum and 1 % penicillin/streptomycin mixture
(Life Technologies, Carlsbad, CA, USA). The invasive
potential of the cells was determined using BD BioCoatTM
BD MatrigelTM Invasion Chamber (BD Biosciences, MA,
USA).
Cell viability assay
Lapatinib-sensitive and lapatinib-resistant cells were mixed
in different proportions (percentage of resistant cells per
probe was: 0; 5; 10; 25; 50; 75 or 100 %). Combinations of
SKBR-3 cells and their lapatinib-resistant counterparts
(total concentration: 2 9 103 per well in 100 ll of med-
ium) were seeded into 96-well plate and incubated at 37 C
and 5 % CO2 for 24 h. After that time, the medium was
removed and fresh medium containing either lapatinib
(100 nM), one of ITCs (2.5 lM sulforaphene, 5 lM sul-
foraphane or 5 lM erucin) or combinations of compounds
were added. After 48 h cells were incubated with 26 ll of
MTT (4 mg/ml) for additional 3 h. Then, the medium was
removed and formazan crystals were dissolved in 100 ll of
DMSO. Absorbance (570 and 660 nm) was measured in
Victor3 Multilabel Counter (PerkinElmer, USA). Each
dose of ITC and lapatinib was tested in triplicate and the
experiment was repeated twice.
Western blotting
Drug-sensitive and drug-resistant SKBR-3 cells were
mixed in different proportions and seeded in 4 ml of
medium in 6-cm plates. After 24 h, the medium was
removed and replaced with a new one, containing lapatinib
(100 nM), erucin (5 lM) or combination of compounds.
After 48 h, cells were collected and cell lysates, SDS-
PAGE electrophoresis and immunoblotting were per-
formed as described previously [18]. To estimate the
intracellular level of VEGF protein, cells were seeded in
8 ml of medium in 10-cm plates and allowed to attach for
24-h and treated with erucin, the drug or their combination
for 96 h. The intensity of the immunoreactive bands was
determined by densitometric scanning to quantify changes
in protein levels. Each protein was detected at least twice,
from independently prepared lysates.
Migration assay
1 9 106 cells were seeded in 4 ml of medium in 6 cm
plates and a wound was made after 3 days, when cells
achieved 100 % confluence as described by Burk [31].
Cells were washed twice with PBS and a fresh medium
containing 5 lM erucin and/or 100 nM lapatinib was
added. After incubation for 7 days (the medium was
exchanged every 2 days) cells were photographed using a
light microscope. Experiment was performed three times.
Migration was quantified by measuring the distance that
cells migrated from the wound edge, at three positions of
each photo taken from five randomly selected fields.
Invasion assay
The effect of erucin–lapatinib treatment, as well as each of
this agent alone, on in vitro invasion was determined using
BD BioCoatTM BD MatrigelTM Invasion Chamber
according to the manufacturer’s instructions. Briefly, after
rehydratation of the chambers with serum-free medium for
2 h at 37 C, 6 9 104 cells were seeded in serum-free
medium supplemented with the tested agents or DMSO in
each matrigel-coated insert containing membrane with an
8 lm pore size. The lower compartment of the chamber
contained 0.75 ml of medium with chemoattractant (10 %
FBS). After 48 h, matrigel and non invading cells were
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removed; invading cells were fixed with 100 % methanol,
stained with crystal violet and counted under light micro-
scope. Experiment was performed in triplicate.
Statistical analysis
Data were analyzed using GraphPad Prism software.
Differences between groups in migration and invasion
tests were analyzed using Student’s t test. Difference was
considered significant at P\0.05. Differences between
groups in viability tests were analyzed using two-way
ANOVA followed by Bonferroni’s multiple comparison
test.
Results
The effect of lapatinib, isothiocyanates and their
combinations on viability of drug-sensitive
and drug-resistant SKBR-3 cells
To investigate the influence of combined treatment on
viability of cell populations consisting of different pro-
portions of lapatinib-sensitive and lapatinib-resistant cells
we used the MTT assay. We chose low doses of isoth-
iocyanates (close to their IC50) and the drug (below IC50
for the sensitive cell line) in combinations, which have
been shown previously to act in a synergistic way [18].
Our model showed that in populations with high per-
centage of sensitive cells lapatinib was almost as effective
as a low dose of an isothiocyanate, however, combined
therapy was the most effective (Fig. 1). When percentage
of resistant cells increased, lapatinib alone was less
effective but low viability level was sustained due to
isothiocyanates activity, either alone or in combination
with lapatinib. Combination of lapatinib and erucin was
the most efficient in cancer cell viability inhibition, even
in the drug-resistant population (Fig. 1b).
Apoptosis induction and cell signaling analysis
upon lapatinib-erucin treatment
To get insight into the mechanism involved in lapatinib
resistance acquisition we compared status of crucial
members of HER2 signaling pathway in non treated drug-
sensitive or drug-resistant SKBR-3 cells. As shown in
Fig. 2a, in lapatinib-resistant cells the basal level of
p-HER2 was much lower than in sensitive cells while the
total level of the receptor was similar. The main HER2
downstream effector, the Akt kinase, was slightly
decreased in populations enriched in lapatinib-resistant
cells. On the other hand, the phosphorylation of ribosomal
protein S6, substrate of mTOR-S6K1 was significantly
lower in the drug resistant population which was accom-
panied by a drop in a total level of this protein (Fig. 2a).
To determinate the mechanism of anti-proliferative
activity of the combination treatment we used the most
effective pair, lapatinib and erucin, and looked at their
effect on the apoptosis induction (PARP cleavage) and
signal transduction pathway downstream of HER2 (p-Akt
and p-S6). In the case of samples exclusively consisting of
sensitive cells, we observed the highest percentage of
cleaved PARP when cells were exposed to combined
therapy, as compared to those treated either with erucin or
lapatinib alone which is consistent with previously pub-
lished results [18]. When the percentage of resistant cells
was increased, PARP cleavage was induced mostly due to
erucin activity (Fig. 2b).
The drop in the level of phosphorylated Akt kinase was
comparable between erucin and erucin with lapatinib-
treated cells, although in case of fully drug-resistant cells
combination of compounds more efficiently decreased
p-Akt than single compounds (Fig. 2b). We also observed
that in the case of sensitive cells, the level of the phos-
phorylated ribosomal protein S6 (p-S6) was reduced by
both erucin and the drug, and although in other samples,
where proportion of sensitive to resistant cells was 3:1, 1:1
or 0:1, lapatinib or erucin activities were lower, combined
treatment still caused the most effective decrease of p-S6
level comparing with effects of single compounds
(Fig. 2b).
Inhibition of motility and invasion of the drug-
sensitive and drug-resistant SKBR-3 cells
by the combination of erucin and lapatinib
As Akt-mTOR pathway regulates cancer cell migration and
invasion, we investigated whether the combined treatment
impacts cell motility using wound-healing assay. Effect of
lapatinib, at used by us concentration, on cell migration
was weak, irrespective of percentage of the drug resistant
cells in the population. However, we noticed that combi-
nations of lapatinib with sulforaphane, erucin or sul-
foraphene significantly inhibited cell migration as
compared to activity of each agent alone (data not shown).
We observed the most effective cell motility inhibition for
the combination of lapatinib with erucin, both in lapatinib-
sensitive (Fig. 3a) and lapatinib-resistant (Fig. 3b) SKBR-
3 cells.
To evaluate the invasive potential of the drug-sensitive
and the drug-resistant SKBR-3 breast cancer cells in
response to erucin, lapatinib and combined treatment, we
used a transwell matrigel invasion assay. We determined,
that combined treatment most efficiently decreased inva-
siveness of both tested cell lines, as compared to the effect
of erucin and the drug alone, however, statistical
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significance was achieved only in the case of the lapatinib-
sensitive cells (Fig. 4). In case of lapatinib-resistant cells,
the invasiveness inhibition was caused mostly by erucin
(Fig. 4b).
As VEGF is one of the most important regulators of
angiogenesis, a complex process that may facilitate
metastasis, we verified its level in cells treated with erucin,
lapatinib or both agents. Our findings indicate that erucin-
lapatinib combination more efficiently decreased the
VEGF level in drug-resistant than drug-sensitive cells
(Fig. 4c).
Discussion
Lapatinib is one of the most efficient drugs against HER2-
positive breast cancer cells, and one of the most frequently
used in therapy at the advanced, metastatic stage. By
blocking intracellular ATP-binding site of the receptors,
(HER2 and EGFR) lapatinib inhibits activation of both
Ras/Raf/MEK/ERK and PI3K/Akt/mTOR/S6K signal
transduction pathways, and consequently, induces cell
cycle arrest in the G1 phase and apoptosis [32]. Lapatinib
inhibits the receptor for a longer time in comparison to
other anti-EGFR drugs, e.g., erlotinib (Tarceva) and gefi-
tinib (Iressa), due to its long dissociation half life that is
more than 300 min. This drug shows activity in case of
breast cancer cell lines that are resistant to trastuzumab.
Lapatinib decreases activation of S6K and IGF-1, two
signaling pathways that are considered as mediators in
trastuzumab resistance [4].
Despite the great success of lapatinib, its use in therapy
often becomes ineffective and after incipient tumor regres-
sion, recurrence of the disease is observed. This progression
is due to primary or acquired resistance [12]. During long-
term lapatinib therapy, on the one hand drug-sensitive cells
are eliminated; on the other hand probability of drug-resis-
tant cell selection increases [13]. Several mechanisms of
acquisition of resistance to lapatinib have been proposed,
e.g., mutations within genes of HER2 or EGFR receptors,
increased signal transduction from estrogen receptor, over-
expression of progesterone receptor, hyperactivation of
PIK3Ca or mutations in genes of the PI3K pathway [11, 12].
Lapatinib also derepresses FOXO3a, which stimulates
transcription of estrogen receptor (ER) and leads to co-de-
pendence on HER2 and ER signaling [33].
One of the potential ways to overcome drug resistance is a
therapy that uses combination of several anti-HER2 drugs,
nonetheless lapatinib-based therapy has adverse events
(rash, diarrhea, cold symptoms, vomiting, anorexia, nausea,
fatigue, headache, gastrointestinal symptoms and hepato-
toxicity) [4, 34]. This problem is evenmore serious in case of
treatment using two or more drugs. For example, preclinical
studies have shown that combination of lapatinib with tras-
tuzumab more efficiently downregulates survivin and indu-
ces apoptosis, than each of these agents alone. However,
trastuzumab may impair cardiac function by causing myo-
cardium damage and despite the fact that the mechanism of
this cardiac dysfunction is not known, it has been suggested
that HER2 may play a protective role for cardiomyocytes
[35]. Thus, side effects are the main limitation of such
combined therapy.
In this work, we developed cell-based model of lapatinib
resistance using HER2- overproducing SKBR-3 cells that
were cultured for a few months in the presence of
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Fig. 1 Isothiocyanates sensitize SKBR-3 cells to lapatinib. Lapa-
tinib-sensitive cells were mixed with lapatinib-resistant cells in
various ratios (percentage of lapatinib-sensitive cells in a given
sample is shown below the graph) and treated for 48 h with 5 lM
sulforaphane (SFN—a), 5 lM erucin (ERN—b), 2.5 lM sul-
foraphene (SF—c), 100 nM lapatinib (L) or combinations. Cell
viability was estimated by MTT assay. Each point is mean (±SE) of
two experiments done in triplicate (error bars are not shown when
they are smaller than the symbols). Significant differences between
single agent treatment and combination treatment for a given
population are indicated as follows: *P\ 0.05; **P\ 0.01;
#P\ 0.001; ns not significant (two-way ANOVA followed by
Bonferroni’s multiple comparison test)
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increasing drug concentrations. IC50 for the parental cell
line was 120 nM, while their lapatinib-resistant derivatives
were able to grow in the presence of more than 600 nM
drug. Resistance was not associated with the loss of HER2
expression or sensitivity to lapatinib because phosphory-
lation of its downstream effectors, such as Akt, was still
inhibited in resistant cells. It indicates that resistance
occurred by an alternative pathway, similarly as has been
previously observed in the case of lapatinib-resistant
BT474 cells [36].
We further worked on mixed cell populations consisting
of the drug-sensitive and the drug-resistant cancer cells in
various proportions which might mimic heterogeneity of
breast tumor in vivo in context of the resistance acquisition
process. We tested efficiency of anticancer activity of lapa-
tinib, one of isothiocyanates (sulforaphane, erucin or sul-
foraphene) and their combinations applied in relatively low
concentrations which have been previously shown towork in
a synergistic way and inhibit downstream elements of the
HER-2 pathway in lapatinib-sensitive cells [18]. Our find-
ings support hypothesis that isothiocyanates sensitize lapa-
tinib-resistant cells to the drug. Even when percentage of the
resistant cells increased, and drug sensitivity decreased,
combination of lapatinib with any of the isothiocyanates
tested caused a decline in cell viability and migration
potential, as compared to activity of each agent alone.
Interestingly, relatively poorly known erucin in combi-
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Fig. 2 a Comparison of the levels and phosphorylation of HER2, Akt
and S6 in populations of lapatinib-sensitive and/or lapatinib-resistant
cells. b Impact of erucin, lapatinib or the combination on PARP
cleavage as well as phosphorylation of Akt and ribosomal S6 in cell
populations composed of lapatinib-sensitive and lapatinib-resistant
SKBR-3 cells. Lapatinib-sensitive and lapatinib-resistant cells mixed
in ratio shown above blots (S:R) were treated with 5 lM erucin (E),
100 nM lapatinib (L) or combination of both compounds for 48 h.
Blots were stripped and reprobed with anti-b-actin antibody to verify
equal protein loading. Densitometric analysis data after correction for
loading control and relative to control are on top of the respective
bands. In case of PARP, the percentage of cleaved band in the whole
amount of PARP is shown. Similar results were observed in replicate
experiments
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combinations. Thus, molecular mechanism was investi-
gated in more details for this combination. The apoptosis
marker, cleaved PARP, was increased in cells treated with
lapatinib-erucin combination although when the percentage
of resistant cells increased, erucin was mostly responsible
for apoptosis induction. The analysis also revealed that the
combination of lapatinib with erucin, similarly as in the
drug-sensitive cells, downregulated PI3K-Akt-mTOR-S6K
pathway, which was evidenced by a decrease in p-AKT and
p-S6. This is an important observation as it has been
reported that PI3K-Akt-mTOR-S6K1 signaling plays
prominent roles in apoptosis suppression, drug resistance
and metastasis. Alterations in this pathway in breast cancers
are often caused by mutations or aberrant expression of
numerous genes, including: HER2, BRCA1, BRCA2,
EGFR1, ERa, PTEN, PI3K, TP53, RB [37, 38]. S6K1 is one
of the regulators of cancer cell invasion, migration and
metastasis. It was demonstrated in a model of metastasis of
triple-negative breast cancer that S6K1 promotes inva-
siveness [39]. Moreover, team led by Dihua Yu has shown
that ErbB2 (HER-2) increases VEGF protein production by
activating S6K in cell lines, xenografts and in human can-
cers [40]. This observation underscored suggestion that S6K
activity may serve as a target for antiangiogenic and anti-
metastatic therapies [40]. In our model, combination of
lapatinib with erucin inhibits S6K more efficiently than
treatment with single agents, as revealed by a drop in
phosphorylation of its main substrate, the ribosomal S6
protein, which might serve as a marker of successful
treatment. Reduced activity of S6K might contribute to the
observed decrease in intracellular VEGF level, as well as
inhibition of motility and invasiveness of SKBR-3 cells. It
is worth mentioning that the combined treatment effectively
decreased VEGF and metastatic potential in drug-resistant
cells, although effect on invasive potential was mostly
exerted by erucin.
In conclusion, the obtained results suggest that appli-
cation of isothiocyanates, especially erucin, as adjuvant
agents during lapatinib therapy is reasonable. This novel
solution may not only inhibit resistance acquisition and
metastasis processes, but may also be less deleterious for




























































Fig. 3 Combination of lapatinib with erucin significantly inhibits cell
migration as compared to activity of each agent alone. Confluent
monolayers of lapatinib-sensitive (a) or lapatinib-resistant (b) SKBR-
3 cells were wounded with a razor blade. After 7 days, migration
through the wound edge was examined under the microscope.
Magnification 94. Data represent the mean ± SE of three indepen-
dent experiments, in each five randomly chosen fields were examined;
*P\ 0.05
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fully understand the potential of this method, further
in vitro and in vivo experiments are required.
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